Activ8 Insights
Monthly Report6 min read

January 2025 Activist Short Selling Report

January 2025 Activist Short Selling Performance Report Executive Summary 5 Total Reports Published +3.26% Average Performance of Stock 20% Success Rate January 2025 proved to be one of the most…

Activ8 Newsroom • December 12, 2025

January 2025 Activist Short Selling Report

January 2025

Activist Short Selling Performance Report

Executive Summary

5
Total Reports Published
+3.26%
Average Performance of Stock
20%
Success Rate
January 2025 proved to be one of the most challenging months on record for activist short sellers, with targets gaining an average of 3.26% following report publication. Of the five campaigns launched, only Capybara Research's attack on Quantum Computing (QUBT) delivered meaningful returns for shorts. Most notably, Hindenburg Research's highly-publicized report on Carvana (CVNA) backfired spectacularly, with shares surging over 23% in the weeks following publication. The month underscores the difficulty of shorting in a bullish market environment, particularly when targeting large-cap names with entrenched investor bases.

Top Performers

Successful Short Campaigns

QUBT
-15.95%
Capybara Research

Only 1 of 5 campaigns resulted in target price decline

Capybara Research's report on Quantum Computing Inc. (QUBT) stood alone as January's sole successful short campaign. The firm accused QUBT of fabricating products, sales, and partnerships, arguing that the company's $2 billion valuation was built entirely on misrepresentations. Capybara characterized the company as embodying a "fake it till you make it" mentality common among promotional tech stocks. The 15.95% decline validates the firm's thesis and demonstrates that thorough fraud-focused research can still generate returns even in difficult market conditions.

Bottom Performers

Failed Short Campaigns

CVNA
+23.31%
Hindenburg Research
TMDX
+7.34%
Scorpion Capital
SIG
+1.21%
The Bear Cave
FTAI
+0.37%
Snowcap
The month's biggest story was Hindenburg Research's comprehensive report on Carvana, alleging phantom financing, related-party dealings, and manipulative accounting. Despite the severity of the accusations, CVNA shares surged 23.31%, demonstrating that even the most respected names in activist short selling can face significant headwinds when targeting stocks with strong momentum and loyal investor bases. Scorpion Capital's explosive report labeling TransMedics "the most grotesque healthcare fraud" similarly failed to move the needle, with TMDX gaining 7.34%.

Market Breakdown

Exchange Distribution

NASDAQ

3 reports (60% of total)

Avg. Impact: +2.49%

NYSE

2 reports (40% of total)

Avg. Impact: +12.26%

Geographic Distribution

United States

4 reports (80% of total)

Targets: FTAI, QUBT, TMDX, CVNA

Bermuda

1 report (20% of total)

Target: SIG (Signet Jewelers)

Geographic Reach

🇺🇸 United States
4 reports
🇧🇲 Bermuda
1 report

Industry Analysis

Industry Reports Target Impact
Technology 1 QUBT (Quantum Computing) -15.95%
Specialty Retail 1 CVNA (Carvana) +23.31%
Healthcare 1 TMDX (TransMedics) +7.34%
Luxury Goods 1 SIG (Signet Jewelers) +1.21%
Industrials 1 FTAI (FTAI Aviation) +0.37%
January's industry distribution was remarkably diverse, with each of the five reports targeting a distinct sector. The lone successful short targeted the technology sector, specifically a promotional quantum computing company. Meanwhile, the retail and healthcare sectors proved particularly resistant to short pressure, with both CVNA and TMDX posting significant gains despite detailed fraud allegations.

Market Cap Analysis

Large Cap Challenge

The largest target by market cap was Carvana ($86.7B), which proved entirely resistant to Hindenburg's allegations. Large-cap stocks with institutional backing and strong momentum continue to be extremely difficult to short effectively.

Small Cap Success

January's only successful short targeted Quantum Computing ($1.75B), the smallest market cap in the sample. This reinforces the pattern that smaller, promotional companies remain the most vulnerable to activist short campaigns.

Ticker Company Market Cap Impact
CVNA Carvana $86.67B +23.31%
FTAI FTAI Aviation $18.16B +0.37%
TMDX TransMedics $4.67B +7.34%
SIG Signet Jewelers $3.58B +1.21%
QUBT Quantum Computing $1.75B -15.95%

Firm Rankings

January 2025 Performance by Firm

Capybara Research
1 Report | -15.95%
Winner
Snowcap
1 Report | +0.37%
Flat
The Bear Cave
1 Report | +1.21%
Miss
Scorpion Capital
1 Report | +7.34%
Miss
Hindenburg Research
1 Report | +23.31%
Major Miss
In a month where most shorts struggled, Capybara Research emerged as the clear standout with their successful QUBT campaign. The firm's focus on promotional micro-cap fraud proved to be the right strategy in a market environment that punished shorts targeting larger, more established companies. Even Hindenburg Research, widely considered the gold standard in activist short selling, faced a significant setback with their Carvana report.

Notable Campaigns

The Carvana Setback

Firm: Hindenburg Research

Target: CVNA | Impact: +23.31%

Fraud Allegations Related Party

Hindenburg alleged Carvana sold approximately $800 million in auto loans to a suspected undisclosed related party, representing 26% of gross profit since April 2024. Despite accusations of phantom financing and manipulative accounting, the stock surged, highlighting the challenge of shorting momentum stocks with strong retail backing.

The Lone Winner: QUBT

Firm: Capybara Research

Target: QUBT | Impact: -15.95%

Successful Promotional Stock

Capybara's report accused Quantum Computing Inc. of fabricating products, sales, and partnerships, arguing the $2 billion valuation was built entirely on misrepresentations. The firm's focus on promotional micro-cap fraud delivered January's only winning short campaign.

TransMedics: "Mafia Medicine"

Firm: Scorpion Capital

Target: TMDX | Impact: +7.34%

Healthcare Fraud $0 Target

Scorpion labeled TransMedics "the most grotesque healthcare fraud" they've seen, alleging Mafia-style organ trafficking, kickbacks, and Medicare exploitation. Despite the explosive allegations and a $0 price target, shares gained over 7%, demonstrating healthcare stocks' resilience to short attacks.

Lab-Grown Diamond Thesis

Firm: The Bear Cave

Target: SIG | Impact: +1.21%

Secular Trend Industry Analysis

The Bear Cave argued that Signet Jewelers faces an existential threat from lab-grown diamonds, which are chemically identical but 1/10th the price. While the thesis may prove correct over time, January saw minimal immediate impact as the stock edged slightly higher.

Strategic Insights

1. Market Conditions Matter

January's 20% success rate underscores how difficult it is to short in a bullish market environment. Even the most detailed fraud allegations struggled to overcome positive sentiment and momentum.

2. Size Matters

The only successful short targeted the smallest company by market cap. Large-cap stocks with institutional backing proved essentially immune to activist pressure this month.

3. Promotional Stocks Remain Vulnerable

Capybara's success with QUBT demonstrates that fraud-focused research on promotional micro-caps remains the most reliable path to short-selling returns.

4. Reputation Alone Isn't Enough

Even Hindenburg Research, with their stellar track record, faced a significant miss. Past success doesn't guarantee future results in activist short selling.

5. Healthcare Stocks Are Resilient

Despite Scorpion's explosive allegations and $0 price target, TMDX gained over 7%. Healthcare companies with unique products often have loyal investor bases that dismiss short reports.

Final Thoughts

Bottom Line

January 2025 will go down as a humbling month for activist short sellers. With targets gaining an average of 3.26% and only one of five campaigns delivering positive returns, the month serves as a stark reminder of the risks inherent in short selling, particularly in bull market conditions.

The stark contrast between Capybara Research's successful fraud-focused campaign on a promotional micro-cap and Hindenburg's failed attack on a large-cap momentum stock illustrates a clear pattern: in today's market, the most reliable short-selling opportunities lie in exposing smaller companies with demonstrably fraudulent practices.

For investors, January's results suggest caution when following even the most reputable short sellers into positions on larger, momentum-driven stocks. The market's appetite for risk and its willingness to overlook serious allegations appears undiminished heading into 2025.